Endovascular Therapy for Acute Stroke with a Large Ischemic Region
April 3, 2023
Dr. Arobelidze Clinical question: Does endovascular therapy for acute stroke with a large ischemic region have better functional outcomes compared to medical therapy alone without increasing the...
A 12-month implantable loop recorder detects more atrial fibrillation than 30-day external monitoring after ischemic stroke
January 7, 2022
Dr. Winget Clinical question: In patients with recent ischemic stroke, does monitoring for 12 months with an implantable loop recorder (ILR) detect more atrial fibrillation (AF) than 30 days with...
No serious CV risks for elderly after Pfizer COVID-19 vaccine
December 2, 2021
A French study adds to other evidence that the Pfizer mRNA COVID-19 vaccine does not increase the risk for serious cardiovascular adverse events in elderly individuals.
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
November 17, 2021
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a phase 3 trial.
Is AFib a stroke cause or innocent bystander? The debate continues
October 5, 2021
Many believe AFib is a risk marker for stroke, but new evidence suggests it may be a causal risk factor.
DOACs best aspirin after ventricular ablation: STROKE-VT
August 2, 2021
Cerebrovascular protection was far better on DOACs after catheter ablation for VT or extrasystoles in the trial and may yet be further improved.
Direct oral anticoagulants: Competition brought no cost relief
July 27, 2021
Medicare Part D spending since 2011 has far outpaced growth in the use of oral anticoagulants.
Statins again linked to lower COVID-19 mortality
July 21, 2021
Patients hospitalized for COVID-19 who had been taking statins had a substantially lower risk of death and severe outcomes than those who weren’t in a large observational study.
Reversal agents curb DOAC-related bleeding but deaths still high
June 17, 2021
The meta-analysis of more than 4,000 patients also showed thrombotic events were more frequent with andexanet than with 4PCC or idarucizumab.
Are left atrial thrombi that defy preprocedure anticoagulation predictable?
June 11, 2021
Features that predispose to such persistent LA thrombi, which are not very rare, could potentially guide more targeted TEE screening before rhythm-control procedures.